Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.67 |
| ▸ | TLR2 | O60603 | 1/20 | 0.62 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | NMT2 | O60551 | 2/20 | 0.50 |
| ▸ | NMT1 | P30419 | 2/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22821587 | 1.00 | SLC6A5 (0.67) | SLC6A5TLR2NOD1DNM1MEN1 | |
| SCHEMBL12640054 | 1.00 | SLC6A5 (0.67) | SLC6A5TLR2NOD1DNM1MEN1 | |
| SCHEMBL9664106 | 1.00 | SLC6A5 (0.67) | SLC6A5TLR2NOD1DNM1MEN1 | |
| SCHEMBL9666267 | 1.00 | SLC6A5 (0.67) | SLC6A5TLR2NOD1DNM1MEN1 | |
| SCHEMBL18735588 | 1.00 | SLC6A5 (0.67) | SLC6A5TLR2NOD1DNM1MEN1 | |
| SCHEMBL9664216 | 1.00 | SLC6A5 (0.67) | SLC6A5TLR2NOD1DNM1MEN1 | |
| SCHEMBL9666062 | 0.98 | SLC6A5 (0.65) | SLC6A5TLR2NOD1DNM1MEN1 | |
| SCHEMBL9667026 | 0.95 | SLC6A5 (0.61) | SLC6A5TLR2NOD1DNM1MEN1 | |
| SCHEMBL22821589 | 0.95 | SLC6A5 (0.61) | SLC6A5TLR2NOD1DNM1MEN1 | |
| SCHEMBL9666574 | 0.95 | SLC6A5 (0.61) | SLC6A5TLR2NOD1DNM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664099-A2 | ADENOVIRAL EPITOPES | Pedersen, Niels Rudi (DK) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023848-A2 | ADENOVIRAL EPITOPES | GARDNER, REBECCA, KATHERINE (GB) | 2005-03-17 | — | — | WO | claimed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | claimed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | claimed |
| US-9096646-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| WO-2015091130-A1 | METHOD FOR IMPROVING THE RECOMBINANT PRODUCTION OF SOLUBLE FUSION POLYPEPTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-20130210709-A1 | CXCR4 Receptor Compounds | ACER THERAPEUTICS INC. | 2013-08-15 | — | — | US | disclosed |
| WO-2010053548-A2 | PTHR1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-1664099-A2 | ADENOVIRAL EPITOPES | Pedersen, Niels Rudi (DK) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023848-A2 | ADENOVIRAL EPITOPES | GARDNER, REBECCA, KATHERINE (GB) | 2005-03-17 | — | — | WO | disclosed |
| EP-1453853-A2 | MIXTURE OF PEPTIDES ORIGINATING FROM A NEF PROTEIN AND APPLICATIONS THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2004-09-08 | — | — | EP | disclosed |
| US-20040115622-A1 | Mixture of peptides originating from a Nef protein and applications thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2004-06-17 | — | — | US | disclosed |
| WO-2002062834-A2 | MIXTURE OF PEPTIDES ORIGINATING FROM A NEF PROTEIN AND APPLICATIONS THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2002-08-15 | — | — | WO | disclosed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | disclosed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210709-A1 | CXCR4 Receptor Compounds | CXCR4, CXCL12, SDF4 | SLC6A5 3188/4885TLR2 886/4885NOD1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.